Hims & Hers Health Inc. (NYSE: HIMS) saw its stock surge 5.45% in after-hours trading on Monday following the release of its impressive third-quarter 2025 financial results and news of potential collaboration with Novo Nordisk for weight loss treatments.
The telehealth company reported Q3 revenue of $600 million, significantly beating analyst expectations of $579.3 million. This represents a 49% year-over-year increase, driven by strong subscriber growth and expanding personalized care offerings. Hims & Hers' subscriber base grew to 2.47 million, up 21% from the previous year, while the average monthly online revenue per subscriber increased to $80 from $67 a year ago.
Adding to investor optimism, Hims & Hers revealed it is in active discussions with Novo Nordisk to make Wegovy injections and Novo Nordisk's oral Wegovy (pending FDA approval) available through its platform. This potential partnership could significantly expand the company's offering in the booming weight loss market. Furthermore, the company raised its full-year 2025 revenue guidance to between $2.335 billion and $2.355 billion, demonstrating confidence in its growth trajectory. The strong quarterly performance and positive outlook have reinforced investor confidence in Hims & Hers' business model and growth potential in the telehealth sector.
